WILMINGTON, Del., May 8 /PRNewswire-FirstCall/ -- Universal Capital Management, Inc. (OTC Bulletin Board: UCMT), a Wilmington, Delaware business development company that provides management and strategic growth resources to emerging growth companies, is pleased to report that Vystar(TM) Corporation ("Vystar") and Alatech Healthcare, LLC announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market and sell Alatech's Envy(TM) condom manufactured with Vytex(TM) Natural Rubber Latex (NRL). The Envy condom will be the first consumer medical product available in the U.S. made from Vystar's patented Vytex(TM) NRL, which has less than 2 micrograms/dm2, virtually undetectable levels, of the antigenic proteins that can cause an allergic response, while retaining and improving upon all the desirable qualities of latex.
The Envy condom will carry labeling that will reflect the lowest antigenic protein content currently available in a natural rubber latex medical device in the U.S. Natural rubber latex contains over 200 proteins, similar to other natural plant materials, of which 13 are known allergens. The Vytex NRL process was created to significantly reduce these known proteins. Vystar's business model is to assist all manufacturers in marketing the Vytex component of their products.
According to Vystar's CEO, William Doyle, "Vystar is thrilled to work with Alatech in introducing the first natural rubber latex condom with this level of reduction in antigenic proteins to the U.S. market. The Envy condom made with Vytex represents a revolutionary consumer product in which the antigenic proteins that can cause allergic reactions to natural rubber latex have been reduced to a virtually undetectable level."
Doyle added that, "Natural rubber latex is known to be the best material for both tactile sensitivity, strength and barrier protection, which are very important in a condom for user acceptance and maximum protection. Now, consumers can have the best material for protection plus the added benefit of the reduced antigenic proteins."
Alatech will market and sell the Envy(TM) NRL condom to retailers and through other distribution channels, and expects the product to be available to consumers in the coming months. More than 50 manufacturing trials are underway worldwide for other products made with Vytex NRL including medical and non-medical gloves, foam mattresses and pillows, bandages, adhesives and more.
According to Michael Queen, CEO of Universal Capital Management, "We believe Vystar is one of UCM's most exciting holdings. The company has come a long way in a short time, from conception to imminent commercialization due in large part to its professional management team headed by Bill Doyle. This market changing event will certainly help Vystar's sales and profits going forward."
About Vystar Corporation: Based in Duluth, GA, Vystar Corporation is a privately-held biotechnology company and the exclusive creator of Vytex(TM) Natural Rubber Latex (NRL). Vytex NRL is a patented, all natural raw material that significantly reduces antigenic proteins found in natural rubber latex and can be used in over 40,000 products. Vystar holds two U.S. patents, and additional pending application, and multiple international patent filing for Vytex(TM) NRL technology. In 2007, Vystar was named a Top 10 Innovative Technology Company in Georgia by the Technology Association of Georgia (TAG). For more information, visit www.vytex.com.
About Alatech Healthcare, LLC
Based in Eufaula, Ala., Alatech Healthcare, LLC is a leading manufacturer and supplier of condoms and latex gloves. For more information, visit www.alatechhealthcare.com.
About Universal Capital Management, Inc.: Universal Capital Management, Inc. is a publicly traded Business Development Company created under the Investment Act of 1940. Its purpose is to assist its portfolio companies with funding and management to facilitate growth, and increase their value. Please refer to the company's website at http://www.unicapman.com/.
Certain matters discussed in this press release are "forward- looking statements." These forward-looking statements can generally be identified as such because the context of the statement will include words, such as "expects," "should," "believes," "anticipates," or words of similar import. Similarly, statements that describe UCM's and Vystar's future plans, objectives or goals are also forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties, including the financial performance of Vystar as appropriate, which would cause actual results to differ materially from those currently anticipated. Although UCM and Vystar believe the expectations reflected in any forward-looking statements are based on reasonable assumptions, they cannot give any assurance that their expectations will be attained. Shareholders, potential investors and other readers are urged to consider these factors carefully in evaluating any forward-looking statements. Certain factors could cause results and conditions to differ materially from those projected in these forward-looking statements, and some of these factors are discussed. These factors are not exhaustive. New factors, risks and uncertainties may emerge from time to time that may affect the forward-looking statements made herein. These forward-looking statements are only made as of the date of this press release and UCM and Vystar do not undertake any obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
|SOURCE Universal Capital Management, Inc.|
Copyright©2009 PR Newswire.
All rights reserved